Category Archives: Pharma & Biotech

Pharma & Biotech Press Releases & News distributed via EuropaWire

Novartis Announces Positive Interim Results for Pluvicto™ in Early-Stage Prostate Cancer, Meeting Primary Endpoint in Phase III PSMAddition Trial

(IN BRIEF) Novartis has announced that its Phase III PSMAddition trial of Pluvicto™ in combination with standard of care (SoC) has met its primary endpoint, showing a significant benefit in radiographic progression-free survival (rPFS) and a positive trend in overall … Read the full press release

Novartis Presents ASCO Data Showing Kisqali’s Efficacy and Tolerability in High-Risk Early Breast Cancer Patients

(IN BRIEF) Novartis has presented new data from the Phase III NATALEE trial at ASCO 2025, showcasing Kisqali’s ability to reduce the risk of recurrence in pre-menopausal patients with high-risk early breast cancer. The data reveals a 33% reduction in … Read the full press release

Eckert & Ziegler Hosts Successful 3rd Boston Radionuclide Theranostics Forum to Shape the Future of Precision Oncology

(IN BRIEF) Eckert & Ziegler successfully hosted the 3rd annual Boston Radionuclide Theranostics Forum, bringing together industry leaders to discuss radionuclide theranostics’ role in transforming precision oncology. The event featured expert presentations on advancements in radiopharmaceuticals, clinical development challenges, and … Read the full press release

Roche’s Fenebrutinib Demonstrates Promising Results with Low Relapse Rates and No Disability Progression in Phase II Multiple Sclerosis Study

(IN BRIEF) Roche presented promising 96-week data from the Phase II FENopta study, showing that its investigational drug, fenebrutinib, significantly reduced relapse rates and prevented disability progression in patients with relapsing multiple sclerosis (RMS). The study revealed an annualized relapse … Read the full press release

Itepekimab Shows Positive Results in COPD Phase 3 Study, Reducing Exacerbations in AERIFY-1 Trial

(IN BRIEF) Itepekimab, developed by Sanofi and Regeneron, met its primary endpoint in the AERIFY-1 phase 3 study for COPD, showing a 27% reduction in moderate or severe exacerbations at 52 weeks. However, the AERIFY-2 study did not achieve the … Read the full press release

Sanofi Completes $600 Million Acquisition of DR-0201 to Enhance Immunology Pipeline and Advance Autoimmune Disease Treatments

(IN BRIEF) Sanofi has completed the acquisition of DR-0201 from Dren Bio, now renamed SAR448501, to enhance its immunology pipeline. This bispecific myeloid cell engager, which has shown promising results in B-cell depletion, may offer potential breakthroughs in autoimmune diseases, … Read the full press release

CVC Strategic Opportunities Sells Entire Stake in Genetic S.p.A., Strengthening the Company’s Global Position

(IN BRIEF) CVC Strategic Opportunities II has successfully exited its investment in Genetic S.p.A., a pharmaceutical CDMO specializing in Respiratory, Ophthalmic, and Oncology therapeutic products. The exit sees NB Renaissance and NB Aurora joining the Pavese family as shareholders. Under … Read the full press release

NIB and Celltechna Collaborate on First Baltics Gene Therapy Centre to Boost Life Sciences Innovation

(IN BRIEF) NIB has financed the Gene Therapy Centre in Lithuania, a groundbreaking facility advancing gene therapy research and manufacturing. Opened in September, it is a critical part of Lithuania’s life sciences sector, contributing to the country’s goal of growing … Read the full press release

GSK’s Blenrep Combinations Receive Approval in Japan for Relapsed or Refractory Multiple Myeloma Treatment

(IN BRIEF) GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or refractory multiple myeloma. The approval follows positive results from the DREAMM-7 and DREAMM-8 phase III trials, … Read the full press release

CTP Develops New Sustainable Production Facility for SCHOTT Pharma at CTPark Jagodina, Expanding Global Manufacturing Network

(IN BRIEF) CTP has successfully developed a state-of-the-art 18,000 sqm production facility for SCHOTT Pharma at CTPark Jagodina, Serbia, where high-quality glass ampoules for vaccines and medications will be produced. This facility is a significant addition to SCHOTT Pharma’s global … Read the full press release

University of Copenhagen Researchers Unveil Biosynthetic Method to Cut the Cost of Taxol and Make Production More Sustainable

(IN BRIEF) Researchers from the University of Copenhagen have made a breakthrough in the biosynthetic production of Taxol, a widely used chemotherapy drug. By identifying the enzymes responsible for the final steps in the biosynthetic pathway of Taxol, the team … Read the full press release

AstraZeneca’s Imfinzi Plus BCG Induction and Maintenance Therapy Significantly Improves Disease-Free Survival in High-Risk Non-Muscle-Invasive Bladder Cancer

(IN BRIEF) The POTOMAC Phase III trial results show that adding Imfinzi to standard BCG induction and maintenance therapy improves disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC). The combination demonstrated significant benefits over BCG alone, with … Read the full press release

AstraZeneca’s Breztri Aerosphere Shows Positive Phase III Results for Uncontrolled Asthma Treatment

(IN BRIEF) Positive results from the Phase III KALOS and LOGOS trials show that AstraZeneca’s Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) significantly improves lung function in patients with uncontrolled asthma, compared to dual-combination ICS/LABA therapy. The trials demonstrate the potential of Breztri … Read the full press release

Sanofi Sells 50% Stake in Opella to CD&R, Establishing Independent Global Consumer Healthcare Champion

(IN BRIEF) Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare division, Opella, to CD&R, creating a global leader in consumer healthcare. Sanofi retains a significant 48.2% stake, while Bpifrance will hold 1.8% and join … Read the full press release

Merck to Acquire SpringWorks Therapeutics, Expanding Leadership in Rare Tumors and Advancing Healthcare Innovation

(IN BRIEF) Merck has entered into a definitive agreement to acquire SpringWorks Therapeutics for approximately $3.9 billion. This acquisition will significantly enhance Merck’s rare tumor portfolio, adding first-in-class therapies for desmoid tumors and NF1-PN. The deal aligns with Merck’s strategy … Read the full press release

Sanofi’s Foundation S and Sobi Renew Partnership with WFH Humanitarian Aid Program

(IN BRIEF) Sanofi and Sobi have renewed their partnership with the World Federation of Hemophilia (WFH) to support the WFH Humanitarian Aid Program for up to five years. The new agreement includes the donation of up to 100 million international … Read the full press release

Evotec Achieves Major Milestones in Molecular Glue Degrader Collaboration with Bristol Myers Squibb, Unlocks $75 Million in Payments

(IN BRIEF) Evotec SE has reached key milestones in its molecular glue degrader collaboration with Bristol Myers Squibb, earning $75 million in performance- and program-based payments. The partnership, built on Evotec’s AI-driven drug discovery platforms and BMS’s CELMoD™ technology, continues … Read the full press release

Eckert & Ziegler to Supply Clinical-Grade Y90-PentixaTher Doses for Pentixapharm Trials

(IN BRIEF) Eckert & Ziegler Radiopharma GmbH has entered into a clinical manufacturing agreement with Pentixapharm AG to supply GMP-grade Y90-PentixaTher doses for use in ongoing trials. The radiolabeled therapy targets cancers overexpressing the CXCR4 receptor and supports a theranostic … Read the full press release

Basilea Achieves Second Consecutive Sales Milestone for Cresemba in Japan Through Asahi Kasei Pharma Partnership

(IN BRIEF) Basilea Pharmaceutica has received a CHF 1.7 million milestone payment from its partner Asahi Kasei Pharma following continued strong sales of Cresemba® in Japan—marking the second consecutive quarterly milestone. Cresemba, now marketed in over 70 countries, achieved USD … Read the full press release

Roche Unveils AI-Powered Chest Pain Triage Algorithm to Streamline Emergency Cardiac Care

(IN BRIEF) Roche has launched a CE-marked Chest Pain Triage algorithm developed with Universitätsklinikum Heidelberg to improve emergency diagnosis of chest pain. Integrated into the navify® Algorithm Suite, the tool uses high-sensitivity cardiac troponin testing and ESC guidelines to support … Read the full press release